Clinical Trial Update: Effect of STW5 (Iberogast ®) and STW5-II (Iberogast N®) on Transit and Tolerance of Intestinal Gas [Phase 4]

View source ↗

Summary

Phase 4 trial updating the effects of STW5 (Iberogast) and STW5-II (Iberogast N) on transit and tolerance of intestinal gas in IBS and functional dyspepsia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Functional Dyspepsia
• Irritable Bowel Syndrome

Drugs mentioned

• STW5 (Iberogast) (Iberogast)
• STW5-II (Iberogast N) (Iberogast N)

Snippet

Sponsor: Hospital Vall d'Hebron | Conditions: Irritable Bowel Syndrome, Functional Dyspepsia | Phase 4 | Status: COMPLETED